ISTP, 8025 Lamon Ave. Skokie, Il 60077

LanzaTech – Dow: Collaboration

LanzaTech Global, Inc., the carbon recycling company transforming waste carbon into sustainable raw materials, has collaborated with Dow to introduce a new biodegradable surfactant to the home care market.

Dow’s surfactant, EcoSense™ 2470, is made using LanzaTech’s CarbonSmart™ technology and ensures immediate market entry, while maintaining high-performance standards and advancing sustainability with recycled carbon materials. Surfactants are a critical ingredient for creating the foam and cleaning action of many household cleaning and laundry products.

LanzaTech’s biorecycling technology works like a brewery: proprietary bacteria consume carbon-rich pollution from industrial facilities, such as steelmaking plants, and convert it into CarbonSmart™ chemicals, such as ethanol. This ethanol can be converted into ethylene oxide, and subsequently used to produce surfactants.

This recycled carbon-based surfactant, marketed by Dow as EcoSense™ 2470, has versatile properties suitable for diverse home care applications.

“The capacity to provide cleaning solutions made from recycled carbon with outstanding effectiveness is a distinguishing factor that significantly influences the purchasing decisions of household consumers,” said Farooq Alam, Global Strategic Marketing Director, Dow Home Care. “EcoSense™ 2470 underscores our dedication to eco-conscious surfactant manufacturing, serving as the gateway to a sustainable future. It sends a resounding message to both home care brand owners and consumers that sustainability and superior performance work hand-in-hand harmoniously.”

“There is enough carbon above ground to make all the things we need,” said Jennifer Holmgren, CEO of LanzaTech. “We have been active in the ethoxylates space for several years, converting ethanol to surfactant ingredients, and with now Dow, our collaboration will enable us to greatly expand our reach in this market.”

Click for the complete announcement.

Comments Off on LanzaTech – Dow: Collaboration Blog, News

Read more

Cour: New COO

COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, announced the appointment of Dannielle Appelhans as Chief Operating Officer. In this role, Ms. Appelhans will oversee and execute the Company’s research and development, technical development, technical operations, and quality as well as be a significant contributor to corporate strategy and other business operations.

Ms. Appelhans served most recently as the Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded and clinical-phase biopharmaceutical company pioneering cellular medicines. She previously served as its Chief Operating Officer, where she oversaw corporate strategy, communications, quality, technical development, and operations.

Prior to joining Rubius, she worked at Novartis and held roles of increasing responsibility in operations and strategy culminating in her serving as Senior Vice President of Technical Operations and Chief Technical Officer at Novartis Gene Therapies, where she oversaw late-stage clinical development and commercial manufacturing.

Said John J. Puisis of COUR, “Dannielle’s operating experience will be pivotal in accelerating COUR’s therapeutic programs and positioning COUR in becoming a world class leader in antigen-specific immune tolerance.”

Click for the complete announcement.

Comments Off on Cour: New COO Blog, News

Read more

Mattiq: World Changing Ideas

Mattiq formerly Stoicheia , a company revolutionizing electrochemical process development to achieve the commercially viable sustainable production of chemicals and fuels, announced it’s a recipient in the prestigious 2023 World Changing Ideas Awards from Fast Company.

The awards program honors companies innovating to deliver transformative benefits to society.  The award recognized Mattiq for its first-in-kind approach to developing and commercializing technologies that will decarbonize chemical and fuel production, which remains one of the hardest-to-abate sectors. Key focus areas include the reduction or elimination of scarce, expensive metals like iridium for clean hydrogen production and the conversion of biomass into net-zero chemicals and fuels.

Mattiq’s technology enables industrial partners to accelerate the process of bringing best-in-class electrochemical solutions to market, reducing production costs, carbon footprint, and supply chain risk.

“It’s thrilling to see the creativity and innovation that are so abundant among this year’s honorees,” says Fast Company editor-in-chief Brendan Vaughan.

To learn more about this award, click here.

Comments Off on Mattiq: World Changing Ideas Blog

Read more

Vetter Skokie Demonstrates Success

Drug development of novel therapeutics is increasing, and a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to meet the demand for complex fill and finish solutions. While the stages of early drug development are challenging, Vetter, a leading global Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge. The family-owned company offers comprehensive and expert manufacturing services for clinical trials to support a product’s path to commercialization. A testament to this commitment is evidenced by the success of its Skokie facility located at the Illinois Science + Technology Park, which has already contributed to bringing five new client products to market since it began full operations in 2011. Another four are expected to launch in the next months.

Since the site opened, 240+ customer audits have been successfully completed; the facility has performed over 45 media fills without failure. Vetter Development Service currently runs 80+ projects in phase I and II of clinical development. The US facility has executed 30+ transfers from its early clinical projects to Germany for late-stage development.

“Our clinical manufacturing sites are essential to Vetter’s commercial business pipeline. The Skokie site has demonstrated an impressive track record of success since its opening twelve years ago,” says Dr. Susanne Lemaine, Vice President Vetter Development Services US. “In the last year alone, we acquired more than 10 new customers with promising molecules. Overall, our ongoing investments in clinical filling capabilities are proof of Vetter’s consistent, strategic approach to keeping on track with the market, with a focus on the important drug development needs of our customers.”

For the complete summary, click here.

Comments Off on Vetter Skokie Demonstrates Success Blog, News

Read more

Health Care & Life Sciences

Chicago Health Care and Life Sciences Real Estate Conference @ISTP.

Chicagoland is a leader in healthcare and an emerging life sciences hub. Attendees gained exclusive insights into the latest trends and actionable strategies to incorporate old and new techniques to improve the overall patient experience.

The program covered the future of Chicago’s life sciences sector as thought leaders discussed where the future of the asset class is headed. What does the market need for continued growth and expansion and what challenges are being faced? Industry leaders discussed how owners and developers are capitalizing on the healthcare and life sciences industries.

Topics included:

CHICAGOLAND’S EMERGENCE AS A LIFE SCIENCES HUB – How the City is Positioning Itself to Attract Highly Sought-After Investment and Best-in-Class Innovation

HEALTHCARE REPORT – Dissecting Chicagoland’s Development Pipeline, Tech and Operations, the Latest Innovations, and More!

STRATEGIC LAB DESIGN & CONSTRUCTION
Best Practices for New-Build Facilities and Adaptive Reuse Lab Space

For more pictures of this event, click here. 

For a complete program outline, click here.

 

Comments Off on Health Care & Life Sciences Blog, Events

Read more

Skokie Homewood Suites by Hilton

A groundbreaking ceremony for the Skokie Homewood Suites by Hilton took place on 8/11. Representatives from the community, the Village of Skokie, construction management and hotel development noted their visions and contributions.

The development will include –

• 143 rooms, each with a private kitchenette
• 10,000 square foot indoor/outdoor event space with a capacity of 300
• Suites to accommodate long term stays
• A rooftop bar with views of the Chicago Skyline and Lake Michigan
• Pedestrian arcade to highlight the community
• Ground floor retail (tenants TBD) with rotating pastries and savory snacks.

For more pictures, click here. 

For more information, click here. 

Comments Off on Skokie Homewood Suites by Hilton Blog, Events

Read more

LanzaTech Goes Public

Skokie-based LanzaTech, is a biotech company that works to recycle carbon waste into everyday products and materials like fuels, fabrics and packaging. LanzaTech announced its plans to enter the public market through a merger with special purpose acquisition company AMCI Acquisition Corp. II. The deal will make it the first carbon capture and transformation business in the public space, according to the company.

When the acquisition closes, the combined company is expected to trade under the Nasdaq ticker symbol “LNZA.” The transaction will raise about $275 million in proceeds, money LanzaTech plans to put toward executing its business plan, accelerating commercial operations, funding partner development projects and building out its tech. The deal is set to close in the third quarter of 2022.

“LanzaTech revolutionary technology repurposes waste carbon for use as a feedstock to make the products we use in our daily lives—from yoga pants to jet fuel,” said Dr. Jennifer Holmgren, LanzaTech’s CEO. “Our carbon recycling technology is like retrofitting a brewery onto an emission source like a steel mill or a landfill site, but instead of using sugars and yeast to make beer, pollution is converted by bacteria to fuels and chemicals.”

“We are showing the world what is possible when we radically rethink how we source, use and dispose of carbon. We are excited to be on this journey,” Holmgren further noted.

For more details, click here.

Comments Off on LanzaTech Goes Public Blog, Events

Read more

Cour Pharma Expands at ISTP

To meet the increasing demand for medical research space in the Chicagoland area, Cour Pharmaceuticals’ life science and emerging biotechnology footprint is expanding within the Illinois Science and Technology Park in Skokie, Ill. With the addition, Cour Pharmaceuticals now leases around 25,000 sq. ft. in the park.

COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.

“Continued rapid growth for high-potential life science startups are emerging in Chicago and in addition to talent, life sciences companies like COUR will continue to need access to more specialized wet and dry lab space along with capital,” said COUR Pharmaceuticals CEO John Puisis.

 

Comments Off on Cour Pharma Expands at ISTP Blog, News

Read more

ISTP Ownership Changes

These recent sales highlight property types for which real estate investors have clamored during the COVID-19 pandemic: high-quality life sciences research buildings and office buildings with big, single tenants with good credit and long-term leases. The former has benefited from a rush of venture capital pouring into biotech and pharmaceutical research throughout the public health crisis, while the latter has drawn buyers looking for safe places to invest amid economic uncertainty

A venture of Hallandale Beach, Fla.-based TopMed Realty bought the 233,588 -square-foot office building at 4901 Searle Parkway. The building, which is almost fully leased to NorthShore University HealthSystem on a long-term deal, was purchased from a venture of Skokie-based American Landmark Properties

The sale comes a month after American Landmark sold the life sciences lab portion (8025 and 8045 Lamon Ave.), the majority of the leased 22.6-acre ISTP campus to Chicago-based investor Singerman Real Estate. The portfolio is comprised of a mix of highly technical wet lab and GMP space and is home to established global life sciences brands as well as prestigious university affiliated venture backed startups.

Noted Sam DiFrancesca and Lucas Borges of the JLL Capital Markets team…. “We were encouraged by the depth of capital with an interest in Greater Chicago and are excited to see such an established national life sciences investor as Singerman committing to the market,” “The level of lender interest in this portfolio is further testament to Chicago’s significant growth potential within the life sciences space.” Max Zwolan and Scott Brandwein of JLL also supported the transaction and will continue to handle the leasing for the buyers.
For the entire article, click here.

Comments Off on ISTP Ownership Changes Blog, News

Read more

NU Record Research Funding

Northwestern Research Funding- Record $893M.  Northwestern University’s research enterprise once again demonstrated strong performance, with annual sponsored funds reaching a new record high of $893.4 million for the fiscal year that closed Aug. 31. This represents an increase of 1% from last year’s total and continues a decade-long trend that has positioned Northwestern among the nation’s most prestigious research institutions. Since 2011, the University’s research funding has increased more than 74% as Northwestern approaches $1 billion in sponsored support, a feat achieved by only its top academic peers.

“The remarkable depth and breadth of Northwestern research continues to make a huge positive impact, transforming entire fields and strengthening society,” Milan Mrksich, vice president for research. said. “As we continue to go from strength to strength — including important investments in our entrepreneurial and innovation ecosystem to increase translation — we will enhance our already superb research enterprise to keep elevating Northwestern’s reputation as a premier destination for the best scholars, scientists and students in the world.”

“Our research portfolio now includes a higher percentage of larger, complex awards, reflecting the collaborative approach to research that Northwestern fosters,” said Shandra White, executive director of Sponsored Research. “Having diverse projects within Northwestern’s research landscape is vital, along with the robust infrastructure to support the complexity of those high-impact investigations.”

For more about NU, click here.

Comments Off on NU Record Research Funding Blog, News

Read more